VuCOMP, Inc., leading developer of advanced computer vision systems for the detection of breast cancer, is pleased to announce the successful completion of the development of structured reporting (SR) for CAD marks for digital breast tomosynthesis images.
With this feature, VuCOMP has added the tomosynthesis slice information into the SR so that workstations will have the ability to display the CAD marks directly on the tomosynthesis slices. Additionally, tomosynthesis findings will be shown as enhanced marks on the 2D images.
VuCOMP is working closely with the workstation vendors to continue to enhance the integration process.
This feature will be made available as part of VuCOMP’s M-Vu CAD System for breast tomosynthesis. The M-Vu CAD System for breast tomosynthesis is currently under review by the Food and Drug Administration (FDA), pending approval.
Jim Pike, President and CTO of VuCOMP, stated, “Integration of our CAD markings on tomosynthesis images via the various workstations currently deployed is a major milestone in our development of the first commercially available CAD solution for digital breast tomosynthesis. The SR output is a critical step as we continue to progress down the development path. It has been important for us to work out the details of displaying marks on tomosynthesis slices so that once the FDA approves a CAD system for tomosynthesis, we will have a mechanism in place for appropriate display on the slices.”
The M-Vu® CAD system was the first mammography CAD product to meet the rigorous FDA standard that recommends comprehensive reader studies to prove the effectiveness of CAD systems. VuCOMP continues to provide systematic product updates, fulfilling the company’s commitment to ongoing enhancements for its customers.
Source credit: VuCOMP, Inc.
